Streetbeat News

Price Targets

SCPH

HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on scPharmaceuticals (NASDAQ:SCPH) and maintained an $18 price target.

Portfolio Pulse from richadhand@benzinga.com

June 08, 2023 | 10:17 am

AADI

HC Wainwright & Co. analyst Robert Burns reiterated a Buy rating on Aadi Bioscience (NASDAQ:AADI) and maintained a $45 price target.

Portfolio Pulse from richadhand@benzinga.com

June 08, 2023 | 10:16 am

KNTE

HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on Kinnate Biopharma (NASDAQ:KNTE) and maintained a $24 price target.

Portfolio Pulse from richadhand@benzinga.com

June 08, 2023 | 10:15 am

REPL

HC Wainwright & Co. analyst Robert Burns reiterated a Buy rating on Replimune Group (NASDAQ:REPL) and maintained a $51 price target.

Portfolio Pulse from richadhand@benzinga.com

June 08, 2023 | 10:14 am

COGT

HC Wainwright & Co. analyst Robert Burns maintains a Buy rating on Cogent Biosciences (NASDAQ:COGT) but lowers the price target from $28 to $27.

Portfolio Pulse from richadhand@benzinga.com

June 08, 2023 | 10:13 am

VERA

HC Wainwright & Co. analyst Ed Arce reiterated a Buy rating on Vera Therapeutics (NASDAQ:VERA) and maintained a $10 price target.

Portfolio Pulse from richadhand@benzinga.com

June 08, 2023 | 10:12 am

STOK

HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Stoke Therapeutics (NASDAQ:STOK) and maintained a $35 price target.

Portfolio Pulse from richadhand@benzinga.com

June 08, 2023 | 10:11 am

FHTX

HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Foghorn Therapeutics (NASDAQ:FHTX) and maintained a $20 price target.

Portfolio Pulse from richadhand@benzinga.com

June 08, 2023 | 10:09 am

HCP

Needham analyst Alex Henderson maintains a Buy rating on HashiCorp (NASDAQ:HCP) but lowers the price target from $39 to $34.

Portfolio Pulse from richadhand@benzinga.com

June 08, 2023 | 10:08 am

TD

Credit Suisse analyst Amanda Abraham upgrades Toronto-Dominion Bank (TSX:TD) from Neutral to Outperform and raises the price target from C$85 to C$88.

Portfolio Pulse from richadhand@benzinga.com

June 08, 2023 | 10:04 am